Literature DB >> 31044307

Patient-reported outcomes of the relative severity of side effects from cancer radiotherapy.

Patrick A Williams1, Shu Cao2, Dongyun Yang3, Richard L Jennelle4.   

Abstract

PURPOSE: It is not known which side effects (SEs) cancer patients undergoing definitive radiotherapy (RT) perceive as worse than others. Our objectives were to (1) identify the worst SEs in patients receiving definitive RT-predominant treatment using patient-reported outcomes and (2) investigate the prominence of physical SEs relative to psychosocial SEs.
METHODS: In a single-center outpatient radiation oncology clinic, patients were surveyed on the final day of definitive RT. Sixty-seven cards listed SEs (40 physical and 27 psychosocial), and patients ranked the five most severe. Fifteen points were assigned to the top five selected SEs with descending scores of 5, 4, 3, 2, and 1.
RESULTS: Fifty-five patients completed ≥ 4 weeks of RT with or without concurrent chemotherapy and had not received ≥ 4 weeks of neoadjuvant chemotherapy. Patients with head and neck and pelvis cancers perceived physical SEs as worse relative to psychosocial SEs; physical SEs filled 78% and 69% of the 15 points, respectively. In breast cancer patients, however, psychosocial SEs filled 45% of the 15 points in breast cancer patients (anxiety, depression, and sequelae), compared to 25% in others (P = 0.007). Affects my work, home duties, a SE not associated with the treatment itself, was the most frequently cited psychosocial SE (20% of cohort) and was ranked ninth overall.
CONCLUSION: Perceptions of SEs of cancer RT are dominated by physical quality of life (QoL) concerns and are influenced by the anatomic area receiving RT. Psychosocial QoL concerns are significantly more frequent in breast cancer patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978846.

Entities:  

Keywords:  Health-related quality of life; Patient-reported outcomes; Physical side effects; Psychosocial side effects; Radiation oncology

Mesh:

Year:  2019        PMID: 31044307     DOI: 10.1007/s00520-019-04820-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  6 in total

Review 1.  Co-delivery systems: hope for clinical application?

Authors:  Sepideh Nezhadi; Farid Abedin Dorkoosh
Journal:  Drug Deliv Transl Res       Date:  2021-08-16       Impact factor: 4.617

2.  Study of Antidepressant-Like Effects of Albiflorin and Paeoniflorin Through Metabolomics From the Perspective of Cancer-Related Depression.

Authors:  Danping Zhao; Jianjun Zhang; Yingli Zhu; Cheng He; Wenting Fei; Na Yue; Chenglong Wang; Linyuan Wang
Journal:  Front Neurol       Date:  2022-07-08       Impact factor: 4.086

Review 3.  Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review.

Authors:  Zhi-Jun Yang; Si-Yu Huang; Dan-Dan Zhou; Ruo-Gu Xiong; Cai-Ning Zhao; Ai-Ping Fang; Yun-Jian Zhang; Hua-Bin Li; Hui-Lian Zhu
Journal:  Antioxidants (Basel)       Date:  2022-07-28

4.  A comprehensive pancancer analysis reveals the potential value of RAR-related orphan receptor C (RORC) for cancer immunotherapy.

Authors:  Shengfu He; Jiawen Yu; Weijie Sun; Yating Sun; Mingyang Tang; Bao Meng; Yanyan Liu; Jiabin Li
Journal:  Front Genet       Date:  2022-09-15       Impact factor: 4.772

5.  A Study of Self-Care Practice in Routine Radiotherapy Care: Identifying Differences Between Practitioners and Non-Practitioners in Sociodemographic, Clinical, Functional, and Quality-of-Life-Related Characteristics.

Authors:  Kerstin Stake-Nilsson; Silje Gustafsson; Kristina Tödt; Per Fransson; Anna Efverman
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

Review 6.  Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic Review.

Authors:  Angela M Stover; Rachel Kurtzman; Jennifer Walker Bissram; Jennifer Jansen; Philip Carr; Thomas Atkinson; C Tyler Ellis; Ashley T Freeman; Kea Turner; Ethan M Basch
Journal:  Cancers (Basel)       Date:  2021-07-20       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.